SAWAI GROUP HOLDINGS Co., Ltd. (JP:4887)
:4887
Want to see JP:4887 full AI Analyst Report?
4887 Stock Chart & Stats
¥2359.00
-¥48.50(-2.23%)
At close: 4:00 PM EST
¥2359.00
-¥48.50(-2.23%)
Day’s Range― - ―
52-Week Range¥1,650.00 - ¥2,447.00
Previous CloseN/A
Volume473.80K
Average Volume (3M)299.27K
Market Cap
¥205.51B
Enterprise Value¥314.96B
Total Cash (Recent Filing)¥46.12B
Total Debt (Recent Filing)¥122.49B
Price to Earnings (P/E)13.9
Beta0.42
Next Earnings
May 15, 2026EPS Estimate
27.9Next Dividend Ex-DateN/A
Dividend Yield2.28%
Share Statistics
EPS (TTM)-91.57
Shares Outstanding115,487,140
10 Day Avg. Volume288,420
30 Day Avg. Volume299,266
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)1.41
Price to Sales (P/S)1.30
P/FCF Ratio33.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,741.67Price Target Upside16.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)172.51
Revenue Forecast (FY)¥218.50B
Bulls Say, Bears Say
Bulls Say
Strong TTM Revenue GrowthSawai’s +34% TTM revenue growth indicates durable demand expansion for its pharmaceutical products. Sustained top-line momentum supports scale efficiencies, broader distribution and reinvestment capacity over the medium term, strengthening competitive positioning in generics.
Positive Operating And Free Cash FlowConsistent positive operating cash flow (¥20.3B TTM) and positive free cash flow provide the firm with internal funding for capex, working capital and shareholder returns. Even if variable, ongoing cash generation underpins financial resilience and strategic optionality.
Generics-focused, Integrated Manufacturing ModelA core generics manufacturing and distribution model yields recurring, patent-driven launch opportunities and predictable replacement demand. Vertical manufacturing capability supports supply reliability and unit-cost advantages that can sustain margins over time if managed prudently.
Bears Say
Material Margin CompressionNet margin falling from ~12.1% to ~4.9% TTM signals structural pressure on profitability, whether from pricing, mix shifts, or rising costs. Persistently lower margins would erode cash generation, ROE and capacity to fund investment or dividends over the medium term.
Volatile And Declining Free Cash FlowFCF volatility and a declining trend reduce predictability of discretionary funding. Intermittent negative FCF years constrain reinvestment, debt paydown and distributions, and complicate planning for product launches or capacity expansion over a 2–6 month horizon and beyond.
Rising Leverage And Weaker Returns On EquityHigher leverage increases fixed financial obligations and reduces balance sheet flexibility. Combined with a meaningful drop in ROE, this suggests capital is generating lower returns, limiting ability to absorb shocks or fund organic/ inorganic growth without adding risk.
SAWAI GROUP HOLDINGS Co., Ltd. News
4887 FAQ
What was SAWAI GROUP HOLDINGS Co., Ltd.’s price range in the past 12 months?
SAWAI GROUP HOLDINGS Co., Ltd. lowest stock price was ¥1650.00 and its highest was ¥2447.00 in the past 12 months.
What is SAWAI GROUP HOLDINGS Co., Ltd.’s market cap?
SAWAI GROUP HOLDINGS Co., Ltd.’s market cap is ¥205.51B.
When is SAWAI GROUP HOLDINGS Co., Ltd.’s upcoming earnings report date?
SAWAI GROUP HOLDINGS Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 11 days.
How were SAWAI GROUP HOLDINGS Co., Ltd.’s earnings last quarter?
SAWAI GROUP HOLDINGS Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥42.46 earnings per share for the quarter, missing the consensus estimate of ¥58.03 by -¥15.57.
Is SAWAI GROUP HOLDINGS Co., Ltd. overvalued?
According to Wall Street analysts SAWAI GROUP HOLDINGS Co., Ltd.’s price is currently Undervalued.
Does SAWAI GROUP HOLDINGS Co., Ltd. pay dividends?
SAWAI GROUP HOLDINGS Co., Ltd. pays a Semiannually dividend of ¥28 which represents an annual dividend yield of 2.28%. See more information on SAWAI GROUP HOLDINGS Co., Ltd. dividends here
What is SAWAI GROUP HOLDINGS Co., Ltd.’s EPS estimate?
SAWAI GROUP HOLDINGS Co., Ltd.’s EPS estimate is 27.9.
How many shares outstanding does SAWAI GROUP HOLDINGS Co., Ltd. have?
SAWAI GROUP HOLDINGS Co., Ltd. has 115,487,140 shares outstanding.
What happened to SAWAI GROUP HOLDINGS Co., Ltd.’s price movement after its last earnings report?
SAWAI GROUP HOLDINGS Co., Ltd. reported an EPS of ¥42.46 in its last earnings report, missing expectations of ¥58.03. Following the earnings report the stock price went down -4.582%.
Which hedge fund is a major shareholder of SAWAI GROUP HOLDINGS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4887
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SAWAI GROUP HOLDINGS Co., Ltd.
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.
4887 Stock 12 Month Forecast
Average Price Target
¥2,741.67
▲(16.22% Upside)
Technical Analysis
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Fuji Pharma Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---